Mesnex
(mesna)ApprovedSmall molecule
Mesna is used to protect the bladder from damage caused by certain chemotherapy drugs, particularly when patients receive high-dose chemotherapy treatment for cancer.[2] Mesnex is currently approved and in use across 37 indications[4].[1]
Mesnex is one of 613 small molecule programs targeting Neuroblastoma. It is currently in Approved.
37
Indications
168
Total Trials
41
Active Trials
612
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 37 indications
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Mesnex
BBaxter Healthcare Corporation
Approved
Zofran
NovartisPreclinical
Cabenuva
GSKPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma17 trials
Show 14 more trials
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Terminated·—·Phase 2·NCT00126191·10 enrolled
Acute Lymphoblastic Leukemia14 trials
Show 11 more trials
Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
Terminated·—·Phase 3·NCT00002961·43 enrolled
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT06001385·313 enrolled
Leukemia9 trials
Show 6 more trials
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
Completed·—·Phase 1·NCT00057005·6 enrolled
Neuroblastoma8 trials
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
Completed·—·Phase 2·NCT00578864·13 enrolled
Show 5 more trials
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
Completed·—·Phase 3·NCT00002802·500 enrolled
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
Completed·—·Phase 2·NCT00165139·20 enrolled
Breast Cancer7 trials
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
Completed·—·Phase 2·NCT00006260·36 enrolled
Show 4 more trials
73 more indications
Stem Cell Transplantation6 trials
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
Terminated·—·N/A·NCT00578461·26 enrolled
Show 3 more trials
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
Completed·—·Phase 1·NCT00002854·33 enrolled
Stem Cell Transplantation in Crohn's Disease
Recruiting·—·Phase 1/2·NCT04224558·15 enrolled
Bone Marrow Transplantation6 trials
Soft Tissue Sarcoma5 trials
Systemic Sclerosis4 trials
Stem Cell Transplant to Treat Patients With Systemic Sclerosis
Completed·—·Phase 1·NCT00058578·24 enrolled
Chemotherapy3 trials
Multiple Sclerosis3 trials
Osteosarcoma3 trials
Hematological Malignancies2 trials
Acute Lymphoblastic Leukaemia2 trials
Mantle Cell Lymphoma2 trials
Germ Cell Tumor2 trials
Medulloblastoma2 trials
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02212574·6 enrolled
Hematologic Malignancies2 trials
Stem Cell Transplant2 trials
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
Terminated·—·N/A·NCT00578539·24 enrolled
Memory2 trials
Hematopoietic Stem Cell Transplant2 trials
Transplantation2 trials
Melanoma2 trials
Retinoblastoma2 trials
Ependymoma2 trials
Sickle Cell Disease2 trials
Acute Lymphoblastic Leukemia, in Relapse2 trials
Hematologic Malignancy1 trial
Systemic Lupus Erythematosus1 trial
Allogeneic Hematopoietic Cell Transplant1 trial
Severe Aplastic Anemia1 trial
Tolerance1 trial
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02029638·4 enrolled
Liver Transplant1 trial
Liver Transplantation With Tregs at UCSF
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03654040·42 enrolled
Lymphoid Malignancies1 trial
Adenocarcinoma1 trial
Necrosis1 trial
Ewing sarcoma1 trial
Multiple Myeloma1 trial
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Completed·—·Phase 4·NCT01731886·60 enrolled
Small Cell Lung Cancer1 trial
Kidney Failure1 trial
Effects of Mesna on Homocysteine in Kidney Failure
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT00524199·10 enrolled
Fibrosarcoma1 trial
Vomiting1 trial
Thalassemia1 trial
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
Terminated·—·N/A·NCT00578292·10 enrolled
Patients With Solid Tumors1 trial
Graft-versus-host-disease (GVHD)1 trial
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT00429416·14 enrolled
Ewing's Sarcoma1 trial
Radiation Therapy1 trial
APL1 trial
IS-free Treg HaploHCT
Recruiting·—·Phase 1·NCT04678401·30 enrolled
Hematopoietic Cell Transplantation1 trial
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT04904588·300 enrolled
Myasthenia Gravis1 trial
Idiopathic Inflammatory Myopathy1 trial
Hematologic Cancer1 trial
Liver1 trial
A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation (ITN073ST)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT03577431·9 enrolled
Splenomegaly1 trial
Aplastic Anemia1 trial
Acute Lymphoblastic Leukemia (ALL)1 trial
Peripheral Blood Stem Cell Transplantation1 trial
Metastatic Melanoma1 trial
AML1 trial
Germ Cell Tumors1 trial
CNS Embryonal Tumor1 trial
Unspecified3 trials
Regulatory
FDA Approval Timeline[5]
Dec 30, 1988
MESNEX
NDA NDA019884
Mar 21, 2002
MESNEX
NDA NDA020855
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Mesnex drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for mesna. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBaxter Healthcare Corporation